ARTICLE | Company News
DiNonA, 3SBio deal
August 11, 2014 7:00 AM UTC
DiNonA granted 3SBio exclusive rights to develop and commercialize leukotuximab in Taiwan and China, including Hong Kong and Macau, and in the Middle East, excluding Cyprus, Egypt, Israel and Turkey. ...